NICE | March 2020 | COVID-19 rapid guideline: delivery of radiotherapy [NG162]
The purpose of this guideline is to maximise the safety of patients who need radiotherapy and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for radiotherapy to patient needs if services become limited because of the COVID-19 pandemic.
This guidance was first published on 28 March 2020.
health and care staff involved in planning and delivering services
The recommendations bring together
existing national and international guidance and policies
advice from specialists working in the NHS from across the UK. These include people with expertise and experience of treating patients for the specific health conditions covered by the guidance during the current COVID-19 pandemic.
Colorectal cancer | NICE guideline [NG151] | January 2020
This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and management of secondary tumours (metastatic disease).
NICE | December 2019 | Selective internal radiation therapies for treating hepatocellular carcinoma ID1276 In development [GID-TA10381]
The Department of Health and Social Care has asked the National Institute for Health and Care Excellence (NICE) to produce guidance on using selective internal radiation therapies (SIRT) for treating hepatocellular carcinoma in the NHS in England.
NICE impact reports review how NICE recommendations for evidence-based and cost-effective care are being used in priority areas of the health and care system, helping to improve outcomes where this is needed most. This report considers how NICE’s evidence based guidance can contribute to improvements in the care of people with lung cancer.
Lung cancer is the third most common cancer in England and is the leading cause of cancer death. In 2017, there were almost 39,000 new cases of lung cancer and just over 28,000 related deaths.
Since 2005 and the publication of NICE’s first guideline on lung cancer, NICE has produced a suite of lung cancer related guidance, which aim to improve outcomes by focusing on survival rates and ensuring the most effective tests and treatments are used.
In England, overall survival rates for cancers are improving but there is still a marked difference between lung cancer and other cancers. Between 2012 and 2016 more than 95% of people with breast or prostate cancer survived more than 1 year after their diagnosis, compared to less than 40% of people with lung cancer.
There is an even greater difference between 5-year survival rates. More than 85% of people with breast or prostate cancer survived more than 5 years but just over 15% of people with lung cancer survived this long. When comparing with other countries in Europe, England’s long-term survival for people with lung cancer is poor, ranking 26th out of 29 countries.
Cancer Research UK | October 2019 | Targeted breast cancer treatment approved for NHS use in England
A new treatment for early stage breast cancer will be made available for certain patients on the NHS in England.
Following the recommendation from the National Institute for Health and Care Excellence (NICE), neratinib (Nerlynx) will be offered as an extended treatment for breast cancer patients who’ve had another targeted treatment, trastuzumab (Herceptin), within the last year.
The new treatment is said to “significantly reduce the proportion of breast cancer relapses”, according to short-term trial data.
It’s recommended for use for patients whose cancer tests positive for hormone receptors and a molecule called HER2. The treatment will only be available to adults who’ve been treated with trastuzumab within the last year, and where trastuzumab was used after initial treatment to help stop their cancer coming back.
This is the first treatment available for patients who have previously taken trastuzumab that maintain the intended effect of that treatment (adjuvant therapy).
Further criteria which patients will have to meet in order to access the drug include:
Trastuzumab is the only treatment they’ve taken that targets the molecule HER2
If trastuzumab was given before surgery, there were still signs of cancer in the tissue samples removed during surgery (Source: Cancer Research UK)